EDETOX logo

IN VIVO STUDIES FURTHER DETAILS


BACK TO THE MAIN MENU

back to previous page forward to next page

University of Newcastle homepage

In Vivo Study No: 230

METHODS

ChemicalMembraneConcentration mg/mlConcentration mg/mlloading (mg/cm2)SpeciesSiteArea (cm2)Occluded?Exposure Time (h)Analytical Method
Beta-Estradiol0.020.50.004AcetoneHumanVentral Forearm2.5224Radiolabelled (14C)

RESULTS

Length of Study (h)% Recovery+/-Dose remaining on surface (mg)% remaining on SurfaceDose remaining in stratum corneum (mg)% remaining in stratum corneumDose remaining in the viable skin% remaining in the viable skinAmount Absorbed (mg)% Absorbed+/-% Absorbed
168100.5 0.0097971E-050.1  0.000343.41.23.4
Maximal Flux (mcrg/cm2/h)Average Flux (mcrg/cm2/h)+/-Time Plasma/Blood Levels Peaked (h)Peak Blood Concentration (mg/l)nkp (cm/h)Lag Time (h)
     6  

NOTES

A polypropylene Hilltop Chamber (HTC) was applied but several holes were bored into the plastic, so that the chamber protected the site but did not occlude it. The HTC was removed after 24h and the skin was washed, then a new HTC was added for the duration of the experiment. The Dose left at the surface was determined by adding the amount left in both HTCs to the amount obtained in the wash. Tape stripping of the SC was done at the end of the experiment to determine the amount left in the SC. % Absorption was calculated by measuring the amount exctreted in the urine (not given). This was corrected for incomplete urinary excretion by comparing with the amount excreted after a parenteral dose.

REFERENCE

Bioavailability Of Topically Administered Steroids:: A "Mass Balance" Technique (1988) J. Investig. Dermatol., :29-33